2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

622. Lymphomas: Translational – Non-Genetic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3517 Enhanced NK-cell and T-cell-dependent mechanisms underlie the benefit of epcoritamab combination with rituximab and lenalidomide in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL)

M. Guy Roukens, Annieck M. Diks2, Berris van Kessel-Welmers3, Esther M. van Leeuwen4, Tommy Li5, Christopher Morehouse6, Han Si7, Edith Szafer Glusman, PhD8, PK Epling-Burnette, PhD, PharmD9, Malene Risum, MD, PhD10, Monica Wielgos-Bonvallet, PhD11, Esther Cornelia Wilhelmina Breij12, Andrew J Steele, PhD13, Isil Altintas, PhD14
1 Genmab, Utrecht, Netherlands
2 Genmab, Utrecht, Netherlands
3 Genmab, Utrecht, Netherlands
4 Genmab, Utrecht, Netherlands
5 Genmab, Plainsboro, New Jersey, United States
6 Genmab, Plainsboro, New Jersey, United States
7 Genmab, Plainsboro, New Jersey, United States
8 AbbVie Inc., South San Francisco, California, United States
9 AbbVie, North Chicago, Illinois, United States
10 Genmab, Copenhagen, Denmark
11 Genmab, Plainsboro, New Jersey, United States
12 Genmab, Utrecht, Netherlands
13 Genmab, Plainsboro, New Jersey, United States
14 Genmab, Utrecht, Netherlands

Introduction: In the EPCORE® FL-1 (NCT05409066) trial, fixed-duration epcoritamab (epcor) + rituximab (RTX) and lenalidomide (LEN; R²) demonstrated significantly higher response rates and longer PFS vs R2, with a manageable safety profile in R/R follicular lymphoma (FL), leading to approval in the US/EU. Epcor treatment, as monotherapy (EPCORE NHL-1 [NCT03625037]) and in combination with LEN (EPCORE NHL-5 Arm 1 [NCT05283720]), also demonstrated strong efficacy in R/R diffuse large B-cell lymphoma (DLBCL). Despite high response rates, immune mechanisms supporting the addition of RTX and LEN to epcor remain incompletely defined. We evaluated potential synergies between epcor and RTX-mediated NK-cell cytotoxicity and between epcor and LEN-modulated T-cell effector functions using CD20+ lymphoma models.

Methods: Peripheral blood (PB) NK-cell counts and activation (TCR⁻/CD56⁺ and TCR⁻/CD56⁺/CD69⁺ cells) were assessed by flow cytometry longitudinally in patients with R/R FL or DLBCL treated with epcor monotherapy in EPCORE NHL-1 (NCT03625037) and in patients with R/R FL treated with epcor + R² in EPCORE NHL-2 Arm 2 (NCT04663347). To investigate epcor impact on NK-cell-mediated cytotoxicity, PB mononuclear cells (PBMCs) from healthy donors were co-cultured with CD20⁺ lymphoma cell lines (U-2932 or RCK8) with or without epcor for 24 hours. Pre-exposed NK cells were isolated and co-cultured with CD20+ lymphoma cells in the presence/absence of RTX for 24 hours. NK-cell immunophenotyping and tumor-cell killing were analyzed by flow cytometry. In PBMC co-cultures exposed to a concentration matrix of epcor and RTX for 24 hours, drug synergy was assessed by bivariate response to additive interacting doses model. LEN-mediated immune modulation was examined by co-culturing PBMCs with U-2932 cells in the presence/absence of epcor, LEN, or both for 7 days, followed by analysis of cytokine secretion, cytotoxic granule production, and T-cell cytotoxicity.

Results: In EPCOR clinical trials, epcor monotherapy induced significant (P<0.001) increases in NK-cell numbers, including activated CD69+ NK cells, in patients with R/R FL or DLBCL. Peak median fold-change of NK-cell counts were 1.35 (CD69+ NK cells: 1.8) over baseline in FL and 1.63 (CD69+ NK cells: 1.93) in DLBCL. Comparable levels of NK-cell expansion were observed in patients with R/R FL treated with epcor + R² (peak fold change 1.72; P<0.001). The ability of epcor to enhance RTX-mediated NK-cell cytotoxicity was investigated in vitro. In line with clinical findings, epcor significantly increased NK-cell activation (CD69 expression) in PBMC co-cultures with lymphoma cell lines and after exposure to conditioned supernatants from epcor-treated co-cultures (both P<0.01). Epcor-exposed NK cells also exhibited reduced expression of the inhibitory receptor NKG2A (U-2932: P<0.01; RCK8: P<0.05) and enhanced NK-cell cytotoxicity in the presence of RTX vs control (U-2932: 69% vs 50%, P<0.05; RCK8: 48% vs 39%, P<0.05). Epcor + RTX induced greater tumor cell killing than either agent alone in PBMC cytotoxicity assays with significant synergistic interaction [κ=0.715 (95% CI: 0.170–1.448)], supporting complementary T-cell redirection and NK-cell-mediated cytotoxic mechanisms. The contribution of LEN was examined in PBMC co-cultures with U-2932 cells: epcor + LEN significantly increased secretion of IL-2 (P<0.01), IFNγ (P<0.05), granzyme B (P<0.05), and perforin (P<0.01) compared with epcor alone, while LEN alone had minimal effect on cytokine production. T cells isolated from epcor + LEN-treated co-cultures demonstrated numerically greater tumor cell killing than those treated with epcor or LEN alone.

Conclusions: Epcor induced NK-cell expansion and activation in patients with R/R FL or DLBCL. In vitro, epcor reduced NKG2A expression and enhanced NK-cell activity. Synergy between epcor and RTX increased T- and NK-cell-mediated tumor cell kill. In addition, LEN, in the presence of epcor, increased T-cell effector mechanisms, through IL-2, IFNγ, and cytotoxic granule production. Together, these findings suggest that epcoritamab may broaden immune engagement beyond CD3×CD20-mediated T-cell redirection and provide mechanistic support for combining epcor with RTX and LEN in B-cell NHL, where fixed-duration epcor + R² reduced the risk of progression/death by 79% vs R² after ≥1 prior LOT.

Andrew J Steele, PhD: AbbVie - Current equity holder in publicly-traded company; Johnson & Johnson - Current equity holder in publicly-traded company; Genmab - Stock (publicly traded); Genmab - Current Employment